Literature DB >> 10602729

Persistence of infectious herpes simplex virus type 2 in the nervous system in mice after antiviral chemotherapy.

A M Thackray1, H J Field.   

Abstract

Young adult mice were inoculated with herpes simplex virus type 2 (HSV-2) in the ear pinna. A relatively severe infection resulted, and 45% of the mice died by 11 days postinfection. Therapy at 1 mg/ml by means of the drinking water with either famciclovir for periods of 5 or 10 days or valaciclovir for 5, 10, 15, or 20 days decreased clinical signs and reduced mortality to 15% or less. Throughout a period of 27 days, mice were tested daily for the presence of infectious virus in the ear pinna, brain stem, and ipsilateral trigeminal ganglia. Virus was cleared from these tissues in surviving, untreated animals by 12 days postinfection, and no infectious virus was detected subsequently in any tissue. Furthermore, no infectious virus was detected after day 9 in mice that had been treated with famciclovir. In mice that had received valaciclovir therapy, however, infectious virus was repeatedly detected in the trigeminal ganglia and brain stem tissue samples up to 7 days after treatment was discontinued. To date, no specific mechanism to account for these results has been discovered; however, possible mechanisms for the persistence of potentially infectious virus in neural tissue of treated mice are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10602729      PMCID: PMC89634          DOI: 10.1128/AAC.44.1.97-102.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice.

Authors:  H J Field; P Wildy
Journal:  J Hyg (Lond)       Date:  1978-10

2.  Evidence that neurons harbor latent herpes simplex virus.

Authors:  M L Cook; V B Bastone; J G Stevens
Journal:  Infect Immun       Date:  1974-05       Impact factor: 3.441

3.  Latent herpes simplex virus in spinal ganglia of mice.

Authors:  J G Stevens; M L Cook
Journal:  Science       Date:  1971-08-27       Impact factor: 47.728

4.  Serological properties of thymidine kinase produced in cells infected with type 1 or type 2 herpes virus.

Authors:  M E Thouless
Journal:  J Gen Virol       Date:  1972-12       Impact factor: 3.891

5.  Acyclovir treatment of skin lesions results in immune deviation in mice infected cutaneously with herpes simplex virus.

Authors:  Z Li; H Sato; Y Fukuda; M Kurokawa; S Kageyama; T Kawana; K Shiraki
Journal:  Antivir Chem Chemother       Date:  1999-09

6.  Herpes simplex virus latency: the cellular location of virus in dorsal root ganglia and the fate of the infected cell following virus activation.

Authors:  J L McLennan; G Darby
Journal:  J Gen Virol       Date:  1980-12       Impact factor: 3.891

7.  Herpes simplex virus DNA sequences in the CNS of latently infected mice.

Authors:  C V Cabrera; C Wohlenberg; H Openshaw; M Rey-Mendez; A Puga; A L Notkins
Journal:  Nature       Date:  1980-11-20       Impact factor: 49.962

8.  Acute and recurrent infection with herpes simplex virus in the mouse: a model for studying latency and recurrent disease.

Authors:  T J Hill; H J Field; W A Blyth
Journal:  J Gen Virol       Date:  1975-09       Impact factor: 3.891

9.  Combinations of antiviral and anti-inflammatory preparations for the topical treatment of herpes simplex virus assessed using a murine zosteriform infection model.

Authors:  A R Awan; J Harmenberg; O Flink; H J Field
Journal:  Antivir Chem Chemother       Date:  1998-01

10.  High efficiency latency and activation of herpes simplex virus in human cells.

Authors:  B L Wigdahl; A C Scheck; E De Clercq; F Rapp
Journal:  Science       Date:  1982-09-17       Impact factor: 47.728

View more
  4 in total

1.  Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies.

Authors:  Debra C Quenelle; Bernhardt Lampert; Deborah J Collins; Terri L Rice; George R Painter; Earl R Kern
Journal:  J Infect Dis       Date:  2010-10-05       Impact factor: 5.226

2.  Effect of famciclovir on herpes simplex virus type 1 corneal disease and establishment of latency in rabbits.

Authors:  J M Loutsch; B Sainz; M E Marquart; X Zheng; P Kesavan; S Higaki; J M Hill; R Tal-Singer
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

Review 3.  Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy.

Authors:  Erik De Clercq; Hugh J Field
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

4.  Recurrent vaginal shedding of herpes simplex type 2 virus in the mouse and effects of antiviral therapy.

Authors:  Nicholas Farley; David I Bernstein; Fernando J Bravo; Julie Earwood; Nancy Sawtell; Rhonda D Cardin
Journal:  Antiviral Res       Date:  2010-02-16       Impact factor: 5.970

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.